Key Findings
The performance of Truenat MTB, MTB Plus and MTB-RIF Dx assays show comparable accuracy to the Xpert MTB/RIF and the Xpert Ultra for TB detection (Truenat MTB and Truenat MTB Plus) and for sequential rifampicin resistance detection (Truenat MTB-Rif Dx).
The Truenat MTB and MTB Plus assays also show comparable accuracy to the TB-LAMP assay as replacement tests for sputum smear microscopy. The data for Truenat MTB-Rif shows similar accuracy to WHO-approved commercial line probe assays.
Dr Balram Bhargava, the Director General of the Indian Council of Medical Research, said that this endorsement of the technology by WHO would enable low and middle income countries to procure TrueNat for tuberculosis diagnosis and Rifampicin resistance, so supporting the elimination of the disease in developing countries.
WHO also said that the evidence reviewed supported the continued use of Xpert MTB/RIF and Xpert Ultra as initial diagnostic tests for pulmonary TB in patients of all ages.